- Home
- NMTC vs RNXT Comparison
NMTC vs RNXT Comparison
Compare NMTC & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMTC | RNXT |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6M | 37.4M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NMTC | RNXT |
|---|---|---|
| Price | $0.78 | $0.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $1.98 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 221.2K | 203.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.43 | 59.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,097,692.00 | $43,000.00 |
| Revenue This Year | N/A | $2,995.35 |
| Revenue Next Year | $31.17 | $219.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 163.47 | N/A |
| 52 Week Low | $0.40 | $0.70 |
| 52 Week High | $1.15 | $1.45 |
Technical Indicators
Market Signals| Indicator | NMTC | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 45.87 |
| Support Level | $0.69 | $0.80 |
| Resistance Level | $0.89 | $1.07 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 53.58 | 36.74 |
Price Performance
Historical ComparisonAbout NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.